Early maladaptive internalization of synaptic GABA A receptors (GABA A R) and externalization of NMDA receptors (NMDAR) may explain the time-dependent loss of potency of standard anti-epileptic drugs (AED) in refractory status epilepticus (SE). We hypothesized that correcting the effects of changes in GABA A R and NMDAR would terminate SE, even when treatment is delayed 40 minutes. SE was induced in adult Sprague-Dawley rats with a high dose of lithium and pilocarpine. The GABA A R agonist midazolam, the NMDAR antagonist ketamine and the AED valproate were injected 40 min after SE onset in combination or as monotherapy. The midazolam-ketaminevalproate combination was more efficient than triple-dose midazolam, ketamine or valproate monotherapy or higher-dose dual therapy in reducing several parameters of SE severity. Triple therapy also reduced SEinduced acute neuronal injury and spatial memory deficits. In addition, simultaneous triple therapy was more efficient than sequential triple therapy: giving the three drugs simultaneously was more efficient at stopping seizures than the standard practice of giving them sequentially. Furthermore, midazolam-ketamine-valproate therapy suppressed seizures far better than the midazolam-fosphenytoin-valproate therapy, which follows evidence-based AES guidelines. These results show that a treatment aimed at correcting maladaptive GABA A R and NMDAR trafficking can reduce the severity of SE and its long-term consequences.
Introduction
Pharmacoresistance to benzodiazepines and other drugs (Kapur and Macdonald, 1997; Mazarati et al., 1998) remains a challenge in the treatment of status epilepticus (SE), a life-threatening condition which affects 150,000-200,000 patients per year in the USA and is responsible for 22,000-42,000 deaths yearly (DeLorenzo et al., 1996) . The incidence of SE increased from 3.5 to 12.5/100,000 between 1979 and 2010 (Dham et al., 2014 . Benzodiazepine monotherapy, which is recommended for initial treatment of SE, fails to stop seizures in 35-69% of cases (Glauser et al., 2016; Holtkamp et al., 2005; Mayer et al., 2002; Treiman et al., 1998) .
Studies in experimental models of SE show that early maladaptive internalization of synaptic GABA A receptors (GABA A R) may explain the loss of benzodiazepine potency (Goodkin et al., 2008 (Goodkin et al., , 2005 Kapur and Macdonald, 1997; Mazarati et al., 1998; Naylor et al., 2013 Naylor et al., , 2005 .
The drugs may stop the seizures in the early stage of SE by binding to GABA A R, but progressively lose potency when GABA A R are inactivated by internalization into endosomes. At the same time, glutamatergic excitation, driven by migration of NMDAR subunits toward synapses (Naylor et al., 2013) , is increasing runaway excitation and excitotoxicity. We hypothesized that polytherapy aimed at correcting the consequences of receptor trafficking should reduce SE severity (Niquet et al., 2016b) . Indeed, combinations of a GABA A R agonist and an NMDAR antagonist, such as diazepam and ketamine (Martin and Kapur, 2008) or midazolam and ketamine (Niquet et al., 2016a) have been successful in treating experimental SE and may be synergistic. However, when treatment is delayed, the reduction of the number of synaptic GABA A R makes it difficult to fully restore inhibition with benzodiazepines, and another AED acting at a non-benzodiazepine site is needed to restore the balance between excitation and inhibition. In the present study, we treated 40 min after seizure onset, and combined midazolam and ketamine with the AED valproate. We also studied the timing of drug delivery, since recent studies suggest that it is a major determinant of pharmacoresistance (Silbergleit et al., 2012) , and compared AES guideline-inspired combinations to our combination, which is based on the receptor-trafficking hypothesis. Our results show that the simultaneous administration of midazolam, ketamine and valproate Neurobiology of Disease 104 (2017) [41] [42] [43] [44] [45] [46] [47] [48] [49] 
